DIEM CHU: Open Payments
NPI 1225184955 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,322 in 53 payments from 16 companies in 2025. Trend: 2023 $1,735 · 2024 $3,661 · 2025 $3,322
Food & beverage: $2,985Education: $337
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation | 10 | $807 |
| Astellas Pharma US Inc | 12 | $651 |
| Gilead Sciences, Inc. | 3 | $332 |
| Janssen Biotech, Inc. | 4 | $294 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $220 |
| SOBI, INC | 3 | $176 |
| ABBVIE INC. | 2 | $150 |
| Syndax Pharmaceuticals, Inc. | 3 | $138 |
| PFIZER INC. | 1 | $118 |
| Merck Sharp & Dohme LLC | 3 | $102 |
Products named: NIKTIMVO, Cresemba, Jakafi, Xospata, Vemlidy, LIVTENCITY, Vonjo, DARZALEX.
Industry payments across TX — which companies pay providers there.
